Structure-based rational design of a novel chimeric PD1-NKG2D receptor for natural killer cells

被引:31
作者
Guo, Changjiang [1 ]
Wang, Xiaoyin [1 ]
Zhang, Huiyong [1 ]
Zhi, Lingtong [1 ]
Lv, Tanyu [1 ]
Li, Mingfeng [1 ]
Lu, Chengui [1 ]
Zhu, Wuling [1 ]
机构
[1] Xinxiang Med Univ, Synthet Biol Engn Lab Henan Prov, Sch Life Sci & Technol, Xinxiang, Henan, Peoples R China
关键词
Chimeric receptor; Structure modeling; Rational design; PD-1; NKG2D; Cytotoxicity; NKG2D RECEPTOR; MEMBRANE;
D O I
10.1016/j.molimm.2019.07.009
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Chimeric antigen receptor (CAR)-engineered natural killer (NK) cells have the potential to provide the potential for the implementation of allogeneic "off-the-shelf" cellular therapy against cancers. Currently, most CARs are not optimized for NK cells, so new NK-tailored CARs are needed. Here, a major activating receptor of NK cells, NKG2D was harnessed to design different chimeric receptors that mediate strong NK cell signaling. In these NKG2D signaling-based chimeric receptors, the extracellular domain of inhibitory receptor PD-1 was employed to reverse the immune escape mediated by PD-1 ligands in the solid tumors. To achieve the rational design of chimeric PD1-NKG2D receptors, we developed a transmembrane protein tertiary structure prediction program (PredMP & I-TASSER) and optimized the conformation of the PD-1 ectodomain by genetically altering the sequences encoding the hinge and intracellular domain. Finally, we identified a chimeric PD1-NKG2D receptor containing NKG2D hinge region and 4-1 BB co-stimulatory domain to exhibit stable surface expression and mediate in vitro cytotoxicity of NK92 cells against various tumor cells. This strategy now provides a promising approach for the computer-aided design (CAD) of potent NK cell-tailored chimeric receptors with NKG2D signaling.
引用
收藏
页码:108 / 113
页数:6
相关论文
共 34 条
[11]  
Leslie M, 2018, SCI
[12]  
Li Y, 2018, CELL STEM CELL, DOI [10.1016/j.stem.2018.06.002.0, DOI 10.1016/J.STEM.2018.06.002.0]
[13]   A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors [J].
Liu, Xiaojun ;
Ranganathan, Raghuveer ;
Jiang, Shuguang ;
Fang, Chongyun ;
Sun, Jing ;
Kim, Soyeon ;
Newick, Kheng ;
Lo, Albert ;
June, Carl H. ;
Zhao, Yangbing ;
Moon, Edmund K. .
CANCER RESEARCH, 2016, 76 (06) :1578-1590
[14]   NK cells and cancer: you can teach innate cells new tricks [J].
Morvan, Maelig G. ;
Lanier, Lewis L. .
NATURE REVIEWS CANCER, 2016, 16 (01) :7-19
[15]   Redirected Primary Human Chimeric Antigen Receptor natural Killer Cells As an "Off-the-Shelf immunotherapy" for improvement in Cancer Treatment [J].
Oberschmidt, Olaf ;
Kloess, Stephan ;
Koehl, Ulrike .
FRONTIERS IN IMMUNOLOGY, 2017, 8
[16]   Transcriptional interference by RNA polymerase pausing and dislodgement of transcription factors [J].
Palmer, Adam C. ;
Egan, J. Barry ;
Shearwin, Keith E. .
TRANSCRIPTION-AUSTIN, 2011, 2 (01) :9-14
[17]   Complex regulation of human NKG2D-DAP10 cell surface expression: opposing roles of the γc cytokines and TGF-β1 [J].
Park, Yuk Pheel ;
Choi, Seung-Chul ;
Kiesler, Patricia ;
Gil-Krzewska, Aleksandra ;
Borrego, Francisco ;
Weck, Jennifer ;
Krzewski, Konrad ;
Coligan, John E. .
BLOOD, 2011, 118 (11) :3019-3027
[18]   Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant [J].
Pascolutti, Roberta ;
Sun, Xianqiang ;
Kao, Joseph ;
Maute, Roy L. ;
Ring, Aaron M. ;
Bowman, Gregory R. ;
Kruse, Andrew C. .
STRUCTURE, 2016, 24 (10) :1719-1728
[19]   Engineering Natural Killer Cells for Cancer Immunotherapy [J].
Rezvani, Katayoun ;
Rouce, Rayne ;
Liu, Enli ;
Shpall, Elizabeth .
MOLECULAR THERAPY, 2017, 25 (08) :1769-1781
[20]   NKG2D CARs as Cell Therapy for Cancer [J].
Sentman, Charles L. ;
Meehan, Kenneth R. .
CANCER JOURNAL, 2014, 20 (02) :156-159